Arcturus Therapeutics Holdings Inc.

NASDAQ•ARCT

CEO: Mr. Joseph E. Payne M.Sc.

セクター: Healthcare

業種: Biotechnology

上場日: 2013-05-22

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

連絡先情報

10628 Science Center Drive, Suite 250, San Diego, CA, 92121, United States

858-900-2660

arcturusrx.com

時価総額

$189.87M

PER (TTM)

-2.8

17.9

配当利回り

52週高値

$24.17

52週安値

$5.85

52週レンジ

順位62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$3.08M+0.00%

直近4四半期の推移

EPS

-$1.05+0.00%

直近4四半期の推移

フリーCF

-$16.36M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

KOSTAIVE Commercial Sales Begin First sa-mRNA vaccine sales started in Japan Q4 2024; EU/UK approvals secured validation of platform technology.

R&D Spending Significantly Reduced Total R&D expenses fell 43% to $112.2M in 2025, driven by LUNAR-COVID program transition to commercial phase.

Net Loss Narrowed Substantially Net loss improved to ($65.8M) in 2025 from ($80.9M) in 2024, reflecting lower operating expenses across R&D.

Rare Disease Pipeline Advances ARCT-032 (CF) Phase 2 dosing completed; ARCT-810 (OTC) Phase 2 dosing nearing completion with positive interim data.

リスク要因

Collaboration Revenue Volatility High Total revenue dropped 46% to $82.0M in 2025, heavily reliant on non-recurring milestone payments from CSL Seqirus.

CSL Partnership Financial Strain CSL reported $430M write-down on collaboration citing market decline; potential separation poses further disruption risk.

Future Capital Requirements Expected Expect continued losses; substantial additional capital needed to fund ongoing development and commercialization efforts.

Intellectual Property Litigation Risk Lawsuit filed against AbbVie for trade secret misappropriation; litigation is costly and management attention diversion risk.

見通し

OTC Pediatric Study Planned Type C meeting with FDA scheduled H1 2026 to discuss ARCT-810 future pediatric study under RDEP guidelines.

CF Efficacy Study Initiation Plan to initiate 12-week safety and preliminary efficacy study for ARCT-032 in CF participants in H1 2026.

Platform Technology Expansion Continue exploratory development evaluating genome editing and new targeting approaches for LUNAR and STARR platforms.

Managing High Operating Costs Expect expenses to increase substantially as R&D advances candidates toward and through necessary clinical trials.

同業比較

売上高 (TTM)

VNDA

$216.11M

+8.7%

RGNX

$170.44M

+104.5%

ARCT

$74.12M

-46.4%

粗利益率 (最新四半期)

GOSS

100.0%

+0.0pp

ABSI

100.0%

+197.2pp

VNDA

93.3%

+0.1pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CRVS	$1.28B	-79.2	-23.3%	1.3%
SVRA	$1.07B	-9.8	-84.0%	11.8%
KALV	$856.25M	-4.3	-282.0%	44.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-52.8%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日

EPS:-$1.00

売上高:$6.49M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし